

# SEMINARS IN HUMAN AND TRANSLATIONAL IMMUNOLOGY

Presented by the  
Yale Center for Immuno-Oncology



YaleCME  
CONTINUING MEDICAL EDUCATION

## “Personalized Immunotherapy for the Treatment of Lung Cancer”

### Speaker:

**Roy S. Herbst, MD, PhD**

Ensign Professor of Medicine (Medical Oncology),  
Professor of Pharmacology, Chief of Medical Oncology,  
Yale School of Medicine

**Tuesday, December 3, 2019**

**4:00 – 5:00pm**

**TAC N-203**

#### ACCREDITATION

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

#### TARGET AUDIENCE

The target audience for the HTI Seminar Series comprises attending faculty, clinical and basic scientists, community physicians, nurses, residents, fellows, and students.

#### NEEDS ASSESSMENT

The HTI Seminar Series seeks to review the scientific basis for choice of immunologically related therapeutic targets in various diseases, including organ-specific and systemic autoimmunity, allergy, transplant rejection, cancer, and infectious diseases. The goal is to help understand the rationale and mechanism underlying the major pharmacologic approaches for interventional immunology in current practice and review the data on the different therapeutic approaches in different specialties.

#### LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

1. Understand immunotherapy for lung cancer.
2. Understand the importance of biomarkers to identify patients for immunotherapy.
3. Recognize the value of combination therapy.

#### DESIGNATION STATEMENT

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)<sup>™</sup>. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

#### FACULTY DISCLOSURES

**Roy Herbst:** Has served as a consultant for: Abbvie Pharma., ARMO Biosciences, AstraZeneca, Biodesix, Bolt Biotherapeutics, Bristol-Myers Squibb, Eli Lilly and Co., EMD Serrano, Genentech/Roche, Genmab, Halozyme, Heat Biologics, IMAB Biopharma, Immunocore, Loxo Oncology, Merck and Co., Midas Health Analytics, Mirati Therapeutics, Nektar, NextCure, Novartis, Pfizer, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharma., Symphogen, Takeda, Tesaro, and Tocagen. Has received research support from: AstraZeneca, Eli Lilly and Co., and Merck and Co.

Has served on scientific advisory boards for: Neon Therapeutics, Infinity Pharmaceuticals, and NextCure.

Serves as non-executive board member for Junshi Pharma.

**Stephanie Eisenbarth:** None

**Carrie Lucas:** None

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.

*There is no corporate support for this activity*

**Seminar Host: Aaron Ring, MD, PhD**

Course Directors: Stephanie Eisenbarth, MD, PhD and Carrie Lucas, PhD

For additional information, please contact Allysia Matthews ([allysia.matthews@yale.edu](mailto:allysia.matthews@yale.edu))